血清乙肝表面抗原水平在慢性B型肝炎的临床意义

StephenW

<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01486.x/abstract>
血清乙肝表面抗原水平在慢性B型肝炎
的临床意义


Clinical importance of serum hepatitis B surface antigen levels in chronic
hepatitis B

S. Togo, M. Arai, A. Tawada, T. Chiba, T. Kanda, K. Fujiwara, F. Imazeki,
O. YokosukaArticle first published online: 22 JUL 2011

DOI: 10.1111/j.1365-2893.2011.01486.x

© 2011 Blackwell Publishing Ltd
Issue

Journal of Viral Hepatitis
Early View (Online Version of Record published before inclusion in an
issue)

Summary.  Quantitative serology for hepatitis B surface antigen (HBsAg)
is a new candidate marker for prediction of clinical outcome. The aim of
this study was to investigate the clinical significance of quantifying
HBsAg in patients with hepatitis B virus (HBV) infection. A total of 424
patients who tested positive for HBsAg and were referred to Chiba
University Hospital between January 1985 and April 2008 were included in
the study, and the following characteristics were analyzed: age, gender,
status of hepatitis B e antigen (HBeAg), alanine aminotransferase level
(ALT), HBV DNA level, number of platelets and development of hepatocellular
carcinoma. Measurement of HBsAg was performed using the chemiluminescent
enzyme immunoassay method. The study group consisted of 239 men and 185
women, and their average age was 40.6 ± 14.0 years. HBsAg showed a
positive correlation with HBV DNA level (Pearson’s product moment
correlation, r = 0.586, P < 0.001) and a weak inverse correlation with age
(r = 0.3325, P < 0.001). A control study, matched with age and sex, was
performed between two groups with and without HBeAg seroconversion during
follow-up period. Compared with the age and sex-matched controls, the
change in HBsAg levels per year showed a significant decrease 2 years
before seroconversion (paired t-test, P < 0.05). The serial measurement of
quantitative HBsAg level has the possibility of predicting the occurrence
of HBeAg seroconversion.

StephenW

谷歌翻译不是100％准确，仅供参考使用。

摘要
定量血清乙肝表面抗原（HBsAg的）
临床结果的预测是一个新的候选标记。的宗旨，
本研究的目的是量化的临床意义
乙肝表面抗原与乙型肝炎病毒（HBV）感染的患者。共有424
检测HBsAg阳性的患者被转介到千叶
大学医院1985年1月至2008年4月被列入
的研究，以下几个特点进行了分析：年龄，性别，
乙型肝炎e抗原（HBeAg的状态），谷丙转氨酶水平
（ALT），HBV DNA水平，血小板数量和肝癌发展
癌。使用的化学发光测定的HBsAg
酶免疫分析法。该研究组包括239名男子和185
妇女，她们的平均年龄为40.6±14.0岁。乙肝表面抗原呈
与HBV DNA水平呈正相关（Pearson的产品时刻
相关，r= 0.586，P<0.001）和弱与年龄呈负相关
（R=0.3325，P <0.001）。与年龄和性别相匹配，是一个对照研究，
与两组之间无HBeAg血清学转换期间执行
随访期。年龄和性别匹配的对照，相比
每年在HBsAg水平的变化呈显着下降，2年
血清转换前（配对t检验，P <0.05）。串行测量
定量HBsAg水平的预测发生的可能性
HBeAg血清转换。

一般都能

只比老王的研究慢了一点。

StephenW

一般都能 发表于 2011-7-29 21:16
只比老王的研究慢了一点。

你知不知道他发现了什么?
似乎没有人知道是什么吗.

StephenW

<http://onlinelibrary.wiley.com/doi/10.1002/hep.24473/abstract;jsessionid=51828987FDB7DEDCC2A5E264351BBA71.d03t03>

Clinical utility of hepatitis B surface antigen quantitation in patients
with chronic hepatitis B: A review†‡

Yun-Fan Liaw,§Article first published online: 25 JUL 2011

DOI: 10.1002/hep.24473

Copyright © 2011 American Association for the Study of Liver Diseases
Issue

Hepatology
Volume 54, Issue 2, pages E1–E9, August 2011

Abstract
This clinically relevant review focuses on recent findings concerning
hepatitis B surface antigen (HBsAg) quantitation in untreated patients and
treated patients with chronic hepatitis B. Recent studies and emerging data
have shown that both HBsAg and hepatitis B virus (HBV) DNA levels decline
during the natural course of a chronic HBV infection; they are lowest in
the inactive phase, which is also characterized by the highest HBsAg/HBV
DNA ratio. It has been demonstrated that the combined use of HBsAg and HBV
DNA levels might help in the identification of true inactive carriers with
high accuracy. Retrospective analyses of HBsAg levels in patients
undergoing therapy have suggested a role for HBsAg quantitation in
monitoring the response to therapy. In comparison with nucleos(t)ide
analogues (NAs), interferon-based therapy results in greater overall
declines in serum HBsAg levels. A rapid on-treatment decline in HBsAg
levels appears to be predictive of a sustained response. With the aid of
HBsAg quantitation, it appears that we can anticipate an individualized
approach to tailoring the treatment duration. The proposal of early
stopping rules for patients not responding to pegylated interferon
(according to a lack of any HBsAg decline) represents a step toward a
response-guided approach. The development of stopping rules for patients
treated with NAs is desirable for reducing the need for lifelong therapy.
However, before stopping rules for antiviral therapy can be applied, we
need to learn more about the kinetics of HBsAg declines during the natural
history of the infection and as a response to therapy so that we can better
define the best timing, the relevant HBsAg cutoff levels, and the best ways
to apply these rules in clinical practice. (HEPATOLOGY 2011;)

StephenW

谷歌翻译不是100％正确，仅供参考使用。

摘要
本次临床相关的审查，侧重于关于最近的调查结果
乙肝表面抗原（HBsAg）定量在未经治疗的患者和
与治疗慢性乙型肝炎的近期研究和新兴的数据的病人
表明，HBsAg和乙型肝炎病毒（HBV）DNA水平下降
在一个慢性乙肝病毒感染的自然过程，他们是最低
不活跃的阶段，这也是最高的乙肝表面抗原/乙型肝炎病毒的特点
DNA比例。它已经证明，HBsAg和HBV的结合使用
DNA水平可能帮助识别真正处于非活动状态载体
精度高。患者HBsAg水平的回顾性分析
接受治疗的建议为乙肝表面抗原定量的作用
监测对治疗的反应。在核苷（酸）IDE比较
类似物（NAS），干扰素治疗结果在更大的整体
在血清HBsAg水平的下降。一个快速的治疗上的下降，在HBsAg
水平似乎是预测持续反应。随着援助
乙肝表面抗原定量，看来，我们可以预见，一个个性化的
方法治疗的时间长短剪裁。早期的建议
停止对患者没有响应聚乙二醇干扰素规则
（根据缺乏任何HBsAg的下降）代表走向的一个步骤
响应引导的方法。患者停止规则的发展
与NAS治疗是减少需要终身治疗的理想。
然而，之前停止抗病毒治疗的规则可以适用，我们
需要在自然更了解HBsAg的下降动力学
历史的感染和作为治疗的反应，使我们能够更好地
定义的最佳时机，有关乙肝表面抗原截止水平，和最好的方法
这些规则适用于临床实践。 （肝脏病杂志2011;）

布隆方丹

史蒂芬，你在国外认识人多，消息来源比我们方便，帮忙多找找艾滋病研究的最新进展资料，好吗，hbv这个病，我看还得靠人家发达国家，主要是艾滋的研究进展，啥时候艾滋拿下了，hbv也就小菜一碟，不在话下了

StephenW

布隆方丹 发表于 2011-7-30 19:14
史蒂芬，你在国外认识人多，消息来源比我们方便，帮忙多找找艾滋病研究的最新进展资料，好吗，hbv这个病， ...

"艾滋病研究的最新进展资料" - 根据我们的好朋友Lei Chou，最近有没有新的药.
"主要是艾滋的研究进展，" - 就个人而言，我认为这是开始改变。
"啥时候艾滋拿下了，hbv也就小菜一碟，不在话下了" - 艾滋是一种RNA病毒，B型肝炎是一种DNA病毒.

布隆方丹

StephenW 发表于 2011-7-30 19:25
"艾滋病研究的最新进展资料" - 根据我们的好朋友Lei Chou，最近有没有新的药.
"主要是艾滋的研究进展，" - ...

本质都是一样的，如果hbv简单，早就攻克了
如果有艾滋的最新研究进展，请你记得要及时发上来啊，我们国内不比你外面有办法，得到的资料一半是假的，一半是过期的，除了误导，啥用没有，呵呵

StephenW

回复 布隆方丹 的帖子

个人而言，我想知道丙型肝炎病毒的新药物是否可用于对HBV？